---
figid: PMC6927537__nihms-1544598-f0002
figtitle: Kinase alterations and signaling pathways dysregulated in Ph-like ALL
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
pmcid: PMC6927537
filename: nihms-1544598-f0002.jpg
figlink: pmc/articles/PMC6927537/figure/F2/
number: F2
caption: Kinase alterations and signaling pathways dysregulated in Ph-like ALL. The
  majority of kinase and cytokine receptor alterations converge on two pathways that
  activate JAK-family member signaling or ABL-signaling. Alterations that activate
  JAK-STAT signaling can be targeted with JAK and PI3K inhibitors. ABL-class alterations
  can be targeted with ABL-inhibitors such as dasatinib. Other kinase alterations
  and those that activate Ras signaling can be targeted with specific inhibitors including
  those that inactivate TRK, FLT3, FGFR1, and MEK for the MAPK pathway.
papertitle: How advanced are we in targeting novel subtypes of ALL?.
reftext: Charles G. Mullighan. Best Pract Res Clin Haematol. ;32(4):101095-101095.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9457288
figid_alias: PMC6927537__F2
figtype: Figure
redirect_from: /figures/PMC6927537__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6927537__nihms-1544598-f0002.html
  '@type': Dataset
  description: Kinase alterations and signaling pathways dysregulated in Ph-like ALL.
    The majority of kinase and cytokine receptor alterations converge on two pathways
    that activate JAK-family member signaling or ABL-signaling. Alterations that activate
    JAK-STAT signaling can be targeted with JAK and PI3K inhibitors. ABL-class alterations
    can be targeted with ABL-inhibitors such as dasatinib. Other kinase alterations
    and those that activate Ras signaling can be targeted with specific inhibitors
    including those that inactivate TRK, FLT3, FGFR1, and MEK for the MAPK pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Epo
  - Epx
  - Flt3
  - Jak2
  - Jak3
  - Nras
  - Il2rb
  - Por
  - Arfip2
  - Crlf2
  - Il7r
  - Jak1
  - Kras
  - Csf1r
  - Lyn
  - Fgfr1
  - Zhx2
  - Tyk2
  - Abl1
  - Abl2
  - Pdgfra
  - Pdgfrb
  - Ntrk3
  - ras
  - Hras
  - Rem1
  - Ntrk1
  - Map2k1
  - Stat5a
  - Pik3r1
  - Mtor
  - Crkl
  - Apk
  - Zmym2
  - Etv6
  - EPO
  - TIMP1
  - EPX
  - FLT3
  - JAK2
  - JAK3
  - NRAS
  - IL2RB
  - POR
  - VDAC2
  - CRLF2
  - IL7R
  - INS
  - JAK1
  - KRAS
  - CSF1R
  - LYN
  - FGFR1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - TYK2
  - ABL1
  - ABL2
  - PDGFRA
  - PDGFRB
  - NTRK3
  - HRAS
  - NTRK1
  - TPM3
  - MAP2K1
  - STAT5A
  - STAT5B
  - MTTP
  - DSP-AS1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - CRKL
  - ZMYM2
  - ETV6
  - epoa
  - flt3
  - jak2b
  - jak3
  - nras
  - il2rb
  - pora
  - crlf2
  - il7r
  - ins
  - jak1
  - kras
  - csf1ra
  - lyn
  - si:ch73-206d17.1
  - fgfr1a
  - tyk2
  - abl1
  - abl2
  - pdgfra
  - pdgfrb
  - pak2a
  - itpka
  - rab1ab
  - ntrk1
  - map2k1
  - stat5a
  - mtor
  - crkl
  - zmym2
  - etv6
---
